| Sean M Caples, DO | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Sean M Caples |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 27 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417929449 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 42832 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Mayo Clinic Health System - Albert Lea And Austin | Albert lea, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023177730 PECOS PAC ID: 9537170352 Enrollment ID: O20060509000021 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639198732 PECOS PAC ID: 9537170352 Enrollment ID: O20080108000344 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean M Caples, DO 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Sean M Caples, DO 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.
Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.
Retroviruses such as HIV that are already within cells are much more easily transmitted when they are next to uninfected cells than if they are floating free in the bloodstream.
In today's headlines, a report about the administration's new high-risk pool regulations and how they address abortion coverage, as well as other details related to the new health law and the insurance marketplace.
› Verified 4 days ago
Emily Leasure, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |